2-氨基-5-氯二苯酮肟 | 18097-52-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氨基-5-氯二苯酮肟
• 中文别名: 2-氨基-5-氯二苯甲酮肟
• 英文名称: 2-amino-5-chlorobenzophenone oxime
• 英文别名: 1-(2-Amino-5-chlor-phenyl)-1-phenyl-methanonoxim；(2-amino-5-chlorophenyl)(phenyl)methanone oxime；(2-amino-5-chlorophenyl)(phenyl)methanoneoxime；2-amino-5-chlorobenzophenone α-oxime；2-Amino-5-chlor-benzophenonoxim；2-amino-5-chloro-benzophenone oxime；Methanone, (2-amino-5-chlorophenyl)phenyl-, oxime；N-[(2-amino-5-chlorophenyl)-phenylmethylidene]hydroxylamine
• CAS: 18097-52-4
• 化学式: C₁₃H₁₁ClN₂O
• 分子量: 246.696
• InChiKey: GCAVNCINXJNLED-UHFFFAOYSA-N

物化性质

• 熔点：
  117-120oC
• 沸点：
  434.9±45.0 °C(Predicted)
• 密度：
  1.27±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（少许）、DMSO（少许）、乙酸乙酯（少许）
• 稳定性/保质期：
  遵照规定使用和储存，则不会分解。

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2928000090
• 安全说明：
  S24/25
• 储存条件：
  存于阴凉干燥处

SDS

Name:	2-Amino-5-Chlorobenzophenone Oxime Mixture of Syn and Anti Isomers Material Safety Data Sheet
Synonym:	None known
CAS:	18097-52-4

Section 1 - Chemical Product MSDS Name:2-Amino-5-Chlorobenzophenone Oxime Mixture of Syn and Anti Isomers Material Safety Data Sheet
Synonym:None known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
18097-52-4	2-Amino-5-Chlorobenzophenone Oxime	ca 100	241-999-5

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Clean up spills immediately, observing precautions in the Protective Equipment section. Sweep up or absorb material, then place into a suitable clean, dry, closed container for disposal. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 18097-52-4: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: yellow
Odor: none reported
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: H2NC6H3(Cl)C(=NOH)C6H5
Molecular Weight: 246.70

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, nitrogen oxides, carbon monoxide, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 18097-52-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-Amino-5-Chlorobenzophenone Oxime - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 18097-52-4: No information available.
Canada
CAS# 18097-52-4 is listed on Canada's NDSL List.
CAS# 18097-52-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 18097-52-4 is listed on the TSCA inventory.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

化学性质

目前已知的两种构型，熔点分别为164-167℃和129-132℃。

用途

作为医药中间体使用。

生产方法

由2-氨基-5-氯二苯甲酮与盐酸羟胺反应制得。具体步骤如下：首先，将由异噁唑开环、还原得到的2-氨基-5-氯二苯甲酮反应物调节pH至8后，加入活性炭回流30分钟，趁热过滤。然后，在滤液中加入盐酸羟胺回流10小时。回收75%乙醇后，加水稀释至乙醇浓度为4-5%，冷却至30℃，再加入碳酸钠饱和溶液调节pH值至9。最后，进行过滤，用热水洗涤滤饼至中性，干燥后得到2-氨基-5-氯二苯酮肟。

反应信息

• 作为反应物：
  描述：

  2-氨基-5-氯二苯酮肟 在 sodium hydroxide 作用下， 以 乙醚 、 乙醇 、 水 为溶剂， 反应 3.0h， 生成 舒宁
  参考文献：
  名称：

  取代的 3-Anilino-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepine-2-ones 的合成及其作为胆囊收缩素配体的评价

  摘要：

  3 - 氨基 - 1,4 - 苯二氮卓类以及化学相关的多种胺类由奥沙西泮制备，随后在放射性标记结合测定中对缩胆囊素受体进行筛选。奥沙西泮 2 通过其 3-氯-1,4-苯二氮卓中间体 3 活化，并与大量脂肪族和芳香族胺反应。取代的 3-苯胺基-1,4-苯二氮卓结构被鉴定为一系列不同系列的 3-氨基-1,4-苯二氮卓类 4-38 的先导结构，完整的 SAR（构效关系）优化提供了 3-苯胺基苯二氮卓类 16 -38 具有对 CCK2 的 CCK1 受体选择性。化合物 18、24、28 和 33 对 CCK1 受体的亲和力分别为 11、10、11 和 9 nM。这些等效的 CCK1 配体在行为药理学论文中得到了充分评估。在尾悬垂和 Porsolt 游泳试验中发现了抗抑郁作用。24 和 28 的 ED50 值在这些测定中确定为 0.46 和 0.49 mg/kg。除了抗抑郁作用外，混合拮抗剂 37 还显示出抗焦虑特性。

  DOI：

  10.1002/ardp.200500217
• 作为产物：
  描述：

  2-氨基-5-氯二苯甲酮 在 盐酸羟胺 作用下， 以 乙醇 为溶剂， 反应 10.0h， 以89%的产率得到2-氨基-5-氯二苯酮肟
  参考文献：
  名称：

  从氯甲基-喹唑啉-N-氧化物选择性形成2-氨基取代的1,4-苯二氮卓-4-氧化物和2-氨基甲基-取代的喹唑啉-3-氧化物的机制

  摘要：

  在微扰理论的帮助下解释了邻氨基苯乙酮和二苯甲酮肟 1a-c 与氯乙酰氯到 2-氯甲基-喹唑啉-3-氧化物 6a-c 的转化。6a-c 与氨和底漆反应。脂肪胺环扩展为 1,4-苯并二氮杂卓 16 和 17，具有芳香族和 N-sec。喹唑啉衍生物 10-13 由胺形成；杂环的构成通过核磁共振光谱方法确认。选择性产物的形成可以通过相应的 2-加合物 14 的相对热力学稳定性来解释。

  DOI：

  10.1002/ardp.19943270204

文献信息

• A Practical, Metal-Free Synthesis of 1<i>H</i>-Indazoles
  作者：Carla M. Counceller、Chad C. Eichman、Brenda C. Wray、James P. Stambuli

  DOI：10.1021/ol800053f

  日期：2008.3.1

  The synthesis of 1H-indazoles is achieved from o-aminobenzoximes by the selective activation of the oxime in the presence of the amino group. The reaction occurs with a variety of substituted o-aminobenzoximes using a slight excess of methanesulfonyl chloride and triethylamine at 0-23 degrees C and is amenable to scale-up. The synthesis of 1H-indazoles under these conditions is extremely mild compared

  1H-吲唑的合成是通过在氨基存在下肟的选择性活化，由邻氨基苯并肟实现的。该反应在0-23℃下使用稍微过量的甲磺酰氯和三乙胺与多种取代的邻氨基苯甲酰肟发生，并且可以放大。与以前的合成方法相比，在这些条件下1H-吲唑的合成非常温和，并以良好的产率提供了所需的化合物。
• Salicylic Acid Based Small Molecule Inhibitor for the Oncogenic Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2)
  作者：Xian Zhang、Yantao He、Sijiu Liu、Zhihong Yu、Zhong-Xing Jiang、Zhenyun Yang、Yuanshu Dong、Sarah C. Nabinger、Li Wu、Andrea M. Gunawan、Lina Wang、Rebecca J. Chan、Zhong-Yin Zhang

  DOI：10.1021/jm901645u

  日期：2010.3.25

  homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) plays a pivotal role in growth factor and cytokine signaling. Gain-of-function SHP2 mutations are associated with Noonan syndrome, various kinds of leukemias, and solid tumors. Thus, there is considerable interest in SHP2 as a potential target for anticancer and antileukemia therapy. We report a salicylic acid based combinatorial library approach

  Src homology-2 域包含蛋白酪氨酸磷酸酶-2 (SHP2) 在生长因子和细胞因子信号传导中起关键作用。功能获得性 SHP2 突变与 Noonan 综合征、各种白血病和实体瘤有关。因此，人们对 SHP2 作为抗癌和抗白血病治疗的潜在靶点有相当大的兴趣。我们报告了一种基于水杨酸的组合文库方法，旨在结合活性位点和附近独特的亚袋，以提高亲和力和选择性。文库的筛选导致鉴定出具有高效细胞活性的 SHP2 抑制剂 II-B08（化合物9）。化合物9阻断生长因子刺激的 ERK1/2 激活和造血祖细胞增殖，提供支持证据表明 SHP2 的化学抑制可能对抗癌和抗白血病治疗有治疗作用。与9复合的 SHP2 结构的 X 射线晶体学分析揭示了可用于获得更有效和选择性 SHP2 抑制剂的分子决定因素。
• I₂-Catalyzed oxidative synthesis of <i>N</i>,4-disubstituted quinazolines and quinazoline oxides
  作者：Nagesh Jatangi、Radha Krishna Palakodety

  DOI：10.1039/c9ob00349e

  日期：——

  approach to the synthesis of N,4-disubstituted quinazoline-2-amine and oxides is described. This transformation proceeds smoothly in the presence of molecular iodine. The metal-free protocol presented here is insensitive to air moisture and operationally simple. This versatile and synthetic methodology is broadly applicable to a variety of N,4-disubstituted quinazoline-2-amines and oxides, which are synthesized

  描述了一种简单而有效的合成N，4-二取代的喹唑啉-2-胺和氧化物的方法。在分子碘的存在下，该转化过程顺利进行。此处介绍的无金属协议对空气湿度不敏感，操作简单。这种通用的合成方法广泛适用于各种N，4-二取代的喹唑啉-2-胺和氧化物，从容易获得的廉价前体开始，即可以良好的产率获得优异的合成率。
• Benzophenone anti-oximes, diazepin-N-oxides, and their use as
  申请人：E. I. Du Pont de Nemours and Company

  公开号：US04182760A1

  公开（公告）日：1980-01-08

  N-Fluorohaloacetyl-N-methylaminobenzophenone anti-oxime, the corresponding diazepin-N-oxides, their use as tranquilizers, muscle relaxants and sedatives, and their use as intermediates in the preparation of 3-fluorobenzodiazepines, which are also useful as tranquilizers, muscle relaxants and sedatives.

  N-氟卤代乙酰-N-甲基氨基苯甲酮抗氧化物，相应的二氮杂环氧化物，它们作为镇静剂、肌肉松弛剂和镇静剂的用途，以及它们作为制备3-氟苯二氮杂环化合物的中间体的用途，后者也可作为镇静剂、肌肉松弛剂和镇静剂。
• [EN] NOVEL 3-SUBSTITUTED-1,4-BENZODIAZEPINES<br/>[FR] NOUVELLES 1,4-BENZODIAZEPINES 3-SUBSTITUEES
  申请人：UNIV ASTON

  公开号：WO2004106310A1

  公开（公告）日：2004-12-09

  The present invention relates to compounds of formula (I). The invention also relates to methods for preparing the compounds and their uses as CCK receptor ligands and CCK antagonists.

  本发明涉及式（I）的化合物。该发明还涉及制备这些化合物的方法，以及它们作为CCK受体配体和CCK拮抗剂的用途。